Announcements Trials
Browse Landscape

Phase

Phase 2 37Phase 1 12Phase 3 6Phase 1/2 3Phase NA 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Gynecologic 1

Conditions

Colorectal Neoplasms 38Pancreatic Neoplasms 16Colonic Neoplasms 12Rectal Neoplasms 11Stomach Neoplasms 9Neoplasms 9Neuroblastoma 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Neoplasm Metastasis 7Glioblastoma 7Sarcoma, Ewing 6Gastrointestinal Neoplasms 6Central Nervous System Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Glioma 5Sarcoma 4Brain Neoplasms 4Medulloblastoma 3Intestinal Neoplasms 3Gliosarcoma 3Gastrointestinal Diseases 3Esophageal Neoplasms 3Digestive System Neoplasms 3Digestive System Diseases 3Astrocytoma 3Advanced Solid Tumors 3Recurrence 2Rectal Diseases 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

pembrolizumab 20Paclitaxel 13Fluorouracil 13Docetaxel 13Radiotherapy 12Oxaliplatin 11Cisplatin 11Capecitabine 8Carboplatin 7Leucovorin 6Cetuximab 5Nivolumab 4Albumin-Bound Paclitaxel 4atezolizumab 3Trastuzumab 3Ramucirumab 3Irinotecan 3Interleukin-2 3Injections 3Epirubicin 3Drug Therapy 3Dexamethasone 3130-nm albumin-bound paclitaxel 3tremelimumab 2tisotumab vedotin 2regorafenib 2patritumab deruxtecan 2oblimersen 2nedaplatin 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Esophageal Neoplasms × Irinotecan × Clear all
NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Merck Sharp & Dohme LLC

Phase 1/2 Completed
90 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT01941316 2024-05-09

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Cancer Research and Biostatistics Clinical Trials Consortium

Phase 1/2 Completed
78 enrolled 15 charts
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡